Yanqiu Zhao

Yanqiu Zhao


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LCLi-Juan Chen
Li-Juan Chen
XLXing-Ya Li
Xing-Ya Li
YZYanqiu Zhao
Yanqiu Zhao
WLWen-Jing Liu
Wen-Jing Liu
HWHui-Juan Wu
Hui-Juan Wu
HWHong-Bo Wu
Hong-Bo Wu

1 May 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XMXiaoqian Mu
Xiaoqian Mu
HWHongbo Wu
Hongbo Wu
JLJie Liu
Jie Liu
XHXiufeng Hu
Xiufeng Hu
HWHuijuan Wu
Huijuan Wu
YZYanqiu Zhao
Yanqiu Zhao
Long noncoding RNAs (lncRNAs) play critical roles in the pathogenesis of various diseases, including a variety of tumors. Nevertheless, its functional roles and underlying molecular basis for their dysregulation in lung adenocarcinoma (LUAD) are largely unknown. Herein, in our study, we identified that lncRNA TMPO-AS1 is significantly upregulated in LUAD tissues and cell lines. Knockdown of TMPO-AS1 remarkably suppressed LUAD cell growth, induced apoptosis as well as G1/S arrest, and inhibited LUAD cell invasion, whereas overexpression of TMPO-AS1 exerts the opposite effects. Next, we implemented online database analysis tools to find that mir-383-5p could target TMPO-AS1, and our data showed that TMPO-AS1 was negatively correlated with mir-383-5p in LUAD specimens. We found that inhibiting miR-383-5p expression led to a marked upregulation of TMPO-AS1 level, while overexpression of miR-383-5p markedly suppressed TMPO-AS1's expression and function, suggesting that TMPO-AS1 is negatively regulated by miR-383-5p. In addition, we confirmed that miR-383-5p directly targeted TMPO-AS1 by binding to microRNA binding sites in the TMPO-AS1 sequence with a luciferase reporter and RIP assays. Besides, the inhibition of TMPO-AS1 significantly suppressed the tumorigenesis ability of LUAD cells in vivo. Together, these results demonstrate that TMPO-AS1 could be considered as a potential therapeutic target for LUAD patients.

1 March 2019 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LCLijuan Chen
Lijuan Chen
XHXiufeng Hu
Xiufeng Hu
HWHuijuan Wu
Huijuan Wu
YJYongxu Jia
Yongxu Jia
JLJie Liu
Jie Liu
YZYanqiu Zhao
Yanqiu Zhao

1 June 2019 in Pathology - Research and Practice
Verified
Journal Article
Closed access
LCLijuan Chen
Lijuan Chen
XHXiufeng Hu
Xiufeng Hu
HWHuijuan Wu
Huijuan Wu
JLJie Liu
Jie Liu
XMXiaoqian Mu
Xiaoqian Mu
YZYanqiu Zhao
Yanqiu Zhao

4 June 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LCLijuan Chen
Lijuan Chen
JLJie Liu
Jie Liu
JLJunfeng Lu
Junfeng Lu
XHXiufeng Hu
Xiufeng Hu
EAErjing An
Erjing An
YZYanqiu Zhao
Yanqiu Zhao
Objective: To evaluate the optimal first-line treatment options for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations.Methods: A total of 159 PD-L1-negative LUAD patients without common gene-alterations were included. Chemotherapy was administered in 44 cases (group A), immunotherapy-chemotherapy combinations in 55 cases (group B) and bevacizumab plus chemotherapy in 60 patients (group C). A head-to-head comparison of the clinical effectiveness and safety for these standard treatment regimens was conducted.Results: The median follow-up time was 30.9 months. For the entire cohort, median PFS was 6.67 months [95% CI 5.83-7.51], and median OS was 15.83 months [95% CI 13.46-18.21]. OS was significantly longer in group C versus others (C vs B median 21.6 months [95% CI 17.78-25.42] vs 12.63 months [95% CI 8.14-17.13]; HR 0.59 [95% CI 0.39-0.9], P = 0.01; C vs A median 21.6 months [95% CI 17.78-25.42] vs 13.47 months [95% CI 9.68-17.26], HR 0.47 [95% CI 0.3-0.71], P= 0.001), but no substantial difference was noted between group A and B (HR 0.78 [95% CI 0.51-1.2], P= 0.26). For PFS in pairwise comparison, group B and C were statistically superior to group A (B vs A median 5.6 months [95% CI 4.56-6.64] vs 5.17 months [95% CI 4.09-6.25]; hazard ratio (HR) 0.56 [95% CI 0.37-0.87], P = 0.009; C vs A median 8.57 months [95% CI 7.47-9.66] vs 5.17 months [95% CI 4.09-6.25]; HR 0.43 [95% CI 0.28-0.7], P< 0.001), whereas no significant difference was found between group B and C (HR 0.76 [95% CI 0.51-1.11], P= 0.16). The disease control rate (DCR) improvement was sustained with group C (A vs B vs C: 84.09% vs 83.64% vs 96.67%, respectively (P0.05), and all AEs were manageable without fatal toxicities.Conclusions: Bevacizumab plus chemotherapy should be prioritized in PD-L1-negative LUAD patients without common driver gene alterations. These findings may facilitate individualized treatment options.